Algeness—What do we know about this filler

Abstract

AbstractBackgroundDermal fillers are cosmetic injections that temporarily treat signs of aging. While hyaluronic acid (HA) fillers have been in forefront of the cosmetic industry, non‐HA‐based alternatives have increased in popularity over the past decade. Algeness is an agarose gel‐based dermal filler marketed as a natural and biodegradable alternative to HA. Available in four different concentrations, including 1%, 1.5%, 2.5%, and 3.5% agarose, Algeness has numerous applications ranging from lip augmentations to treatment of nasolabial folds and nonsurgical rhinoplasties. The structure of Algeness closely mimics that of the extracellular matrix and may be advantageous for mitigating migration. Algeness is also not readily digested by a specific human enzyme but is metabolized by macrophages of the reticuloendothelial system instead. These characteristics are thought to contribute to Algeness' durability and volumizing properties. The longevity of the filler directly correlates with the concentration of agarose incorporated, reportedly ranging from 3 to 15 months, depending on the formulation. Injection of Algeness differs from that of HA filler and a linear retrograde injection approach is recommended.ConclusionIn the limited studies performed thus far, Algeness has been shown to have comparable durability, patient satisfaction, and early adverse effects to HA fillers, particularly for treatment of the nasolabial folds. However, Algeness has not yet received Food and Drug Administration approval and is currently not available in US markets. Randomized clinical trials are currently underway to further evaluate its performance and safety.